[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bundang CHA Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":164},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,77,99,121,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100621125","epigenetic-factors-of-colorectal-adenoma-in-korean-100621125",false,"NCT07366554","Epigenetic Factors of Colorectal Adenoma in Korean","Exploration of Epigenetic Factors of Colorectal Adenoma in Korean","* Inclusion Criteria:\n\n  * Adults aged 19-85 years\n  * Undergoing colonoscopic polypectomy for colorectal adenoma\n  * Able to understand the study purpose and provide written informed consent\n  * Adequate tissue available for both adenoma and adjacent normal mucosa sampling\n* Exclusion Criteria:\n\n  * History of colorectal cancer, inflammatory bowel disease, or hereditary colorectal cancer syndrome (e.g., FAP, Lynch syndrome)\n  * Previous colorectal surgery that may alter anatomy or pathology\n  * Inadequate sample quality or failure of DNA extraction\n  * Refusal or withdrawal of informed consent\n  * Severe comorbidities that make participation unsuitable at investigator's discretion","ALL","19 Years","85 Years",{"count":20,"type":21},32,"ESTIMATED","1 Day","OBSERVATIONAL","This study aims to explore epigenetic factors associated with colorectal adenoma (CRA) in the Korean population. CRA is a key precancerous lesion in the adenoma-carcinoma sequence, and identifying methylated genetic markers may improve early detection and risk stratification for colorectal cancer (CRC).\n\nA total of 32 patients undergoing colonoscopic polypectomy will be enrolled. Adenomatous and adjacent normal tissues will be collected for deoxyribonucleic acid (DNA) extraction and bisulfite conversion. Quantitative methylation-specific polymerase chain reaction (qMSP) and Sanger sequencing will be used to assess the methylation status of candidate genes (SFRP2, TFPI2, SEPT9, and SDC2). Stool samples will also be analyzed by whole-genome sequencing (WGS) to evaluate microbiome and genetic profiles.\n\nThe study seeks to determine whether methylation levels of these genes are significantly elevated in adenoma tissue compared with normal mucosa, thereby identifying potential biomarkers for colorectal neoplasia surveillance and personalized colonoscopy follow-up intervals.",[26,27],"Colorectal Adenoma","Colorectal Cancer Precancerous Lesion",[26,29,30,31,32,33,34,35,36,37,38,39],"DNA Methylation","Epigenetics","Biomarker discovery","SFRP2","TFPI2","SEPT9","SDC2","qMSP","Korean population","Colorectal cancer prevention","Adenoma-carcinoma sequence","NOT_YET_RECRUITING","2026-01-25",{"date":43,"type":44},"2026-01-27","ACTUAL",{"date":46,"type":21},"2026-02-10",{"date":48,"type":21},"2027-05-09",{"name":50,"class":51},"Bundang CHA Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":52},"100591603","the-effect-of-magnetic-stimulation-on-low-back-pain-relief-and-muscle-mass-maintenance-in-patients-with-esrd-100591603","NCT06982573","The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With ESRD","The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With End-Stage Renal Disease (ESRD)","Inclusion Criteria:\n\n1. Adults aged 19 years or older\n2. Patients diagnosed with end-stage renal failure and receiving dialysis treatment more than three times a week\n3. Back pain intensity of 4 points or higher on the visual analogue scale (VAS)\n4. Those with cognitive function that can clearly indicate NRS with a score of 23 points or higher, the criterion for determining cognitive impairment on the Mini Mental State Examination (MMSE) \\[14\\]\n5. Those who voluntarily decided to participate in this clinical trial after receiving a detailed explanation and fully understanding it and gave written consent to comply with the precautions\n\nExclusion Criteria:\n\n1. If the pain is due to trauma\n2. If it is difficult to participate in the study due to serious mental illness (e.g. schizophrenia, bipolar disorder, etc.) or psychological instability.\n3. Patients with severe neurological illness (e.g. stroke, severe dementia, etc.).\n4. Those with poor general condition due to unstable cardiovascular, digestive, respiratory, or endocrine systems, or severe internal medical illness such as systemic infection\n5. Patients participating in other therapeutic clinical trials or those who have participated in other therapeutic clinical trials within the past 30 days (observational studies are not relevant)\n6. If there are contraindications to magnetic stimulation\n\n   * Patients with implanted medical devices (e.g. pacemakers)\n   * Metal objects are inserted into the skull\n   * A wound on the skin at the attachment site\n   * History of epilepsy\n   * Cervical pain or musculoskeletal disease\n   * Pregnant and lactating women",{"count":61,"type":21},18,"INTERVENTIONAL",[64],"NA","To determine the effectiveness of magnetic stimulation application on alleviating back pain and maintaining muscle mass in patients with end-stage renal disease.",[67],"End-Stage Renal Disease","RECRUITING","2025-09-15",{"date":71,"type":44},"2025-09-19",{"date":73,"type":44},"2025-08-06",{"date":75,"type":21},"2026-02-19",{"name":50,"class":51},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":4,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":52},"100544364","multicenter-study-on-rehabilitation-medical-data-for-pediatric-big-brain-development-100544364","NCT06367920","Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain Development","Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain","Inclusion Criteria:\n\n* Healthy subjects and patients 20 years old or younger who underwent imaging examinations performed at the Department of Rehabilitation Medicine at our hospital from January 2010 to December 2023 (patients who underwent brain MRI tests to determine the cause of developmental delay)\n\nExclusion Criteria:\n\n* None",true,"20 Years",{"count":87,"type":21},2000,"Retrospective study for development of imaging-genetics (brain imaging\u002Fgenome big data) models and algorithms that are clinically explainable and have high predictive performance in brain research on pediatric developmental disorders",[90,91],"Pediatric ALL","Healthy",{"date":93,"type":44},"2025-09-17",{"date":95,"type":44},"2023-03-23",{"date":97,"type":21},"2026-12-31",{"name":50,"class":51},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":105,"minAge":106,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":62,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100592580","umbilical-cord-blood-therapy-in-a-child-with-eosinophilic-duodenitis-and-autism-spectrum-disorder-a-case-study-100592580","NCT06995274","Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study","Inclusion Criteria:\n\n1. Child aged 4 years at the time of enrollment\n2. Diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder (ASD)\n3. Actively receiving outpatient care at the Department of Rehabilitation Medicine, CHA Bundang Medical Center\n4. Autologous cord blood available and stored at an accredited cord blood bank\n5. Written informed consent provided by a legally authorized representative (parent or guardian) after receiving a full explanation of the study\n\nExclusion Criteria:\n\n1. Presence of a severe uncontrolled medical condition that may interfere with cord blood infusion or study assessments\n2. History of severe allergic reaction to components of the investigational product or immunosuppressive agents (e.g., cyclosporine)\n3. Current or recent participation (within 30 days) in another interventional clinical trial\n4. Any contraindication to MRI, EEG, or fNIRS assessments (e.g., implanted metal device, severe behavioral intolerance)\n5. Determined by the principal investigator to be unsuitable for participation due to safety concerns or noncompliance","MALE","4 Years",{"count":52,"type":21},[64],"This single-case exploratory clinical study aims to evaluate the therapeutic potential of umbilical cord blood (UCB) infusion in a pediatric patient diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder (ASD). ED is a rare inflammatory gastrointestinal condition characterized by excessive eosinophil infiltration in the duodenal mucosa, often associated with immune hypersensitivity and allergic responses. ASD is a neurodevelopmental disorder marked by deficits in social interaction, communication, and behavioral flexibility. Recent evidence suggests a link between gastrointestinal inflammation and neurodevelopmental symptoms via the gut-brain axis, especially in patients with co-occurring ASD and eosinophilic gastrointestinal disorders (EGIDs).\n\nIn this study, the patient will receive three UCB infusions: one autologous and two allogeneic. The first (autologous) UCB is stored at a certified cord blood bank and will be administered intravenously. Subsequently, two allogeneic UCB infusions will be administered six weeks apart using HLA-matched donor units selected from a hospital-based cord blood repository. The cell product will contain a minimum of 3 × 10⁷ total nucleated cells per kg, and donor-recipient compatibility for HLA A, B, and DRB1 will be considered.\n\nTo support immune tolerance and reduce potential adverse responses, a 7-day course of low-dose oral cyclosporine will be administered with each allogeneic infusion. All cord blood handling, thawing, and infusion will be performed in a cell therapy center under standardized protocols.\n\nThe primary aim is to explore the immune regulatory effects and symptom relief following UCB therapy in this rare comorbid case. Assessments will include brain MRI with DTI, EEG, fNIRS, sensory profiles (SP), social communication questionnaires (SCQ), autism rating scales (K-CARS-2), behavioral checklists (CBCL), gastrointestinal endoscopy, and developmental\u002Fcognitive\u002Flanguage assessments (e.g., WISC, WPPSI, GMFM, VMI, SELSI, PRES, FIM). Blood samples will be analyzed for eosinophil counts and gene\u002Fprotein expression related to inflammation, neuroendocrine function, and gut-brain signaling (e.g., TNF-α, IL-6, serotonin, dopamine, GABA, CRH, BDNF).\n\nThis case study will also track safety indicators including vital signs, laboratory panels, and adverse events. The data may inform the feasibility of future therapeutic use of UCB in children with complex immune-neurodevelopmental conditions.",[111,112],"Autism Spectrum Disorder","Eosinophilic Gastrointestinal Disorders","2025-05-27",{"date":115,"type":44},"2025-05-29",{"date":117,"type":21},"2025-06-01",{"date":119,"type":21},"2025-12-31",{"name":50,"class":51},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":62,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100591604","a-prospective-single-center-single-arm-investigator-initiated-exploratory-clinical-trial-to-assess-the-safety-of-repetitive-transcranial-magnetic-stimulation-for-children-and-adolescents-with-autism-spectrum-disorder-100591604","NCT06982586","A Prospective, Single-Center, Single-Arm, Investigator-Initiated Exploratory Clinical Trial to Assess the Safety of Repetitive Transcranial Magnetic Stimulation for Children and Adolescents With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. Aged between 3 and 17 years at the time of enrollment\n2. Clinically diagnosed with Autism Spectrum Disorder (ASD), including assessment using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2)\n3. Currently receiving outpatient care for ASD at the Department of Rehabilitation Medicine, CHA Bundang Medical Center\n4. The participant and their legal guardian have been fully informed of the study and have voluntarily provided written informed consent\n\nExclusion Criteria:\n\n1. Diagnosed with a major neurological condition other than ASD\n2. Epileptiform discharges detected on EEG screening requiring initiation or adjustment of antiepileptic medication\n3. Diagnosed with other psychiatric disorders, such as schizophrenia or major depressive disorder\n4. History of traumatic brain injury, brain tumor, or other significant brain conditions\n5. Deemed unsuitable for participation by the principal investigator\n6. Currently participating in another interventional clinical trial, or has participated in one within the past 30 days (excluding observational studies)\n7. Any of the following contraindications to rTMS:\n\n   * Implanted electronic medical devices (e.g., pacemaker)\n   * Presence of metal implants in the skull\n   * Skin lesions at the stimulation site\n   * History of epilepsy\n   * Cervical spine pain or musculoskeletal disorders\n   * Pregnancy or currently breastfeeding","3 Years","17 Years",{"count":61,"type":21},[64],"This is a prospective, single-center, single-arm, investigator-initiated exploratory clinical trial aimed at evaluating the safety and exploring the efficacy of a medical electromagnetic stimulator delivering low-frequency repetitive transcranial magnetic stimulation (rTMS) in children and adolescents with Autism Spectrum Disorder (ASD). ASD is a neurodevelopmental disorder characterized by deficits in social interaction and communication and restricted, repetitive behaviors. Despite increasing prevalence, effective treatment options remain limited, and the demand for non-invasive, safe interventions continues to grow.\n\nIn this study, a total of 18 participants aged 3 to 17 years with a clinical diagnosis of ASD will be enrolled. Participants will receive rTMS using a medically approved electromagnetic stimulator applied to the dorsolateral prefrontal cortex (DLPFC) - five sessions per week for two consecutive weeks (total of 10 sessions). The first 5 sessions will target the left DLPFC, and the remaining 5 will target the right DLPFC. Each session includes 18 trains of 10-second stimulations at 1Hz frequency with 20-second inter-train intervals. The stimulation intensity is set at 90% of the resting motor threshold (rMT), determined individually using motor evoked potential testing.\n\nThe primary objective of this trial is to assess the safety of low-frequency rTMS in this population, with adverse events such as seizures, headaches, dizziness, and mood changes monitored throughout the trial. Vital signs will also be checked before and after each session. Secondary objectives include exploratory evaluation of rTMS effects on sensory processing (SP), social communication (SCQ), autism severity (K-CARS), behavioral symptoms (CBCL), brain activity changes (fNIRS), and electrophysiological responses (EEG), assessed at baseline, immediately after intervention, and at 1- and 3-month follow-ups.\n\nAll participants will undergo baseline assessments including EEG, SP, SCQ, K-CARS, CBCL, fNIRS, and vital signs. These measures will be repeated after the final rTMS session, and again at 1 and 3 months post-intervention. The trial will be conducted at CHA Bundang Medical Center, led by Principal Investigator Professor Minyoung Kim, Department of Rehabilitation Medicine.\n\nThis exploratory study is designed to provide preliminary evidence for the safety of low-frequency rTMS in ASD and to gather pilot data on its potential therapeutic effects, which may support future randomized controlled trials and clinical applications.",[111],"2025-05-18",{"date":135,"type":44},"2025-05-21",{"date":137,"type":21},"2025-07-01",{"date":139,"type":21},"2027-12-31",{"name":50,"class":51},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":62,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100557875","early-phase-1-a-pilot-clinical-trial-study-to-determine-the-safety-of-the-application-of-a-wearable-medical-electromagnetic-generator-100557875","NCT06543797","A Pilot Clinical Trial Study to Determine the Safety of the Application of a Wearable Medical Electromagnetic Generator","A Prospective, Single-center, Single-group, Investigator-led Exploratory Clinical Trial to Determine the Safety of the Application of a Wearable Medical Electromagnetic Generator.","Inclusion criteria\n\n1. Patients aged 19 to 80 years old\n2. Those who are confirmed to have lesions in only one cerebral hemisphere or one brainstem on brain computed tomography (CT) or brain magnetic resonance imaging (MRI)\n3. Patients with subacute stroke between 2 weeks and less than 3 months after onset\n4. Motor function evaluation The total score is 0 to 56 points based on the FMA of the upper extremity on the affected side \\[1\\], and patients show impairment in upper extremity motor function.\n5. After receiving a detailed explanation of this clinical trial and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to comply with the precautions.\n\nExclusion Criteria:\n\n1. Cases accompanied by existing serious neurogenic diseases such as history of underlying stroke, brain tumor, hypoxic brain injury, epilepsy, or organic brain disease\n2. Cases accompanied by existing serious psychiatric diseases such as major schizophrenia, bipolar disorder, dementia, etc., that are receiving continuous drug treatment before the stroke.\n3. Those with unstable conditions in the cardiovascular, digestive, respiratory, and endocrine systems, or with severe internal diseases such as signs of systemic infection, with unstable vital signs, or with poor overall health with a life expectancy of less than 1 year.\n4. Those with impaired cognitive ability (MMSE less than 10 points)\n5. If there are difficulties in conducting research\n6. If you have difficulty communicating\n7. Other patients who are deemed difficult to participate in this study by the principal investigator.\n8. Patients who are participating in other therapeutic clinical studies or who have participated in other therapeutic clinical studies within the past 30 days (observational studies are not relevant)\n9. Exclusion criteria for repetitive transcranial magnetic stimulation\n10. Patients with medical devices implanted in the body (e.g. pacemaker)\n11. When a metal object is inserted into the skull\n12. If there is a wound on the skin at the attachment site\n13. History of epilepsy\n14. If you have cervical pain or musculoskeletal disease\n15. Pregnant and lactating women","80 Years",{"count":150,"type":21},10,[152],"EARLY_PHASE1","To explore the safety of applying repetitive low-frequency transcranial magnetic stimulation using a wearable medical electromagnetic generator in stroke patients.",[155],"Stroke","2024-08-05",{"date":158,"type":44},"2024-08-09",{"date":160,"type":21},"2024-08-20",{"date":162,"type":21},"2024-12-31",{"name":50,"class":51},""]